Evidence map›Paper›PMID 34638452›Full record

ArticleCancers2021

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera.

Martina Barone, Monica Barone, Francesca Ricci, Giuseppe Auteri, Francesco Fabbri, Erika Bandini, Francesco Francia, Pier Luigi Tazzari, Nicola Vianelli, Silvia Turroni and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Martina BaroneIstituto di Ematologia "Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna,40138 Bologna, Italy.
Monica BaroneDepartment of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
Francesca RicciServizio di Immunoematologia e Trasfusionale, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0003-4387-1415
Giuseppe AuteriIstituto di Ematologia "Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna,40138 Bologna, Italy.
Francesco FabbriIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.ORCID 0000-0002-7885-3025
Erika BandiniIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.ORCID 0000-0002-4378-3573
Francesco FranciaDepartment of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy.
Pier Luigi TazzariServizio di Immunoematologia e Trasfusionale, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Nicola VianelliIstituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Silvia TurroniDepartment of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy.ORCID 0000-0003-2345-9482
Michele CavoIstituto di Ematologia "Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna,40138 Bologna, Italy.
Lucia CataniIstituto di Ematologia "Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna,40138 Bologna, Italy.ORCID 0000-0002-4650-201X
Marco CandelaDepartment of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy.
Francesca PalandriIstituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-8367-5668
Istituto di Ematologia di Bologna · ITUniversity of Bologna · ITAzienda USL di Bologna · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · IT

Funding

Associazione Italiana Contro le Leucemie - Linfomi e Mieloma
6 · The paper itself

Abstract

Polycythemia vera is a myeloproliferative neoplasm with increased risk of thrombosis and progression to myelofibrosis. However, no disease-specific risk factors have been identified so far. Circulating extracellular vesicles (EVs) are mostly of megakaryocyte (MK-EVs) and platelet (PLT-EVs) origin and, along with phosphatidylethanolamine (PE)-EVs, play a role in cancer and thrombosis. Interestingly, circulating microbial components/microbes have been recently indicated as potential modifiers of inflammation and coagulation. Here, we investigated phenotype and microbial DNA cargo of EVs after isolation from the plasma of 38 patients with polycythemia vera. Increased proportion of MK-EVs and reduced proportion of PLT-EVs identify patients with thrombosis history. Interestingly, EVs from patients with thrombosis history were depleted in

Indexed as

biomarkerextracellular vesiclesmarrow fibrosismicrobial DNA cargopolycythemia verathrombosis

Identifiers

PMID34638452
PMCPMC8507916
OpenAlexW3202758431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.